Comparative Pharmacology
Head-to-head clinical analysis: CLOZAPINE versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOZAPINE versus RISVAN.
CLOZAPINE vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atypical antipsychotic; binds to dopamine D4, serotonin 5-HT2A, and adrenergic α2 receptors; weak D2 antagonist with rapid dissociation; also affects histaminergic and cholinergic receptors.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
Initial: 12.5 mg orally once or twice daily; titrate gradually by 25-50 mg/day to target dose 300-450 mg/day in divided doses; max 900 mg/day.
70 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 8 to 12 hours (steady-state), but can range from 4 to 66 hours; requires dose adjustment in renal/hepatic impairment.
Clinical Note
moderateClozapine + Norfloxacin
"Clozapine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClozapine + Torasemide
"The risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide."
Clinical Note
moderateClozapine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Clozapine is combined with Etacrynic acid."
Clinical Note
moderateClozapine + Furosemide
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Approximately 50% of the dose is excreted in urine (30% as unchanged drug and metabolites) and 30% in feces via biliary elimination.
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic
"The risk or severity of adverse effects can be increased when Clozapine is combined with Furosemide."